Biotech Funding

The startups leading the longevity capital flow in 2026, ranked. Altos Labs, Oura, Retro Biosciences and the new entrants reshaping longevity investment.

Family offices are no longer curious about longevity. They are building it. UBS projects an $8 trillion market by 2030 - surpassing AI. Here is where the conviction capital is going, who is leading the shift, and what the five capital patterns look like in practice.

More than $5B in longevity and biotech capital was raised globally between July and November 2025. From reprogramming therapeutics to preventive clinics, the sector is entering a pivotal consolidation phase. Here’s what the new funding wave means for longevity’s future.